CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Gilead GILD

Gilead live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2025 Apr 01, 16:00

Silver news today: Why has the silver price been volatile recently?

Commodities
three barrels of oil, neftechka, and American dollars against the background of a wooden table
Tommy Yap 2025 Mar 31, 21:00

Morning Note: US Jobs Data, Oil Steady on Tariffs, MicroStrategy BTC Bet

Oil Morning Note Cryptocurrencies
Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Japan retail 
Tommy Yap 2025 Mar 29, 21:00

Morning Note: Japan Retail, China PMI, Germany Inflation

Japan Morning Note China
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices
Frances Wang 2025 Mar 27, 16:00

Stock market today: S&P 500, Dow, Nasdaq slip on Trump's tariff escalation

Indices
Frances Wang 2025 Mar 27, 16:00

Forex news today: EUR/USD Struggles to Gain Traction Amid Tariff Threats

Forex

Info

Spread

0.69

Spread (%)

0.6214 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt openen

Woensdag

13:31 - 19:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

139684904960

Uitstaande aandelen

1246630016

Datum winstcijfer (volgende)

2013-01-28

Div. rend.

2025-03-28

Ex-dividenddatum

2025-03-14

Jaarlijks verwachte dividendpercentage

3.16

Jaarlijks verwachte dividendrendement

0.0282

Winst per aandeel

0.38

Meer informatie over dit instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot